美中大咖跨界探AI，年度盛会，早鸟票即将售罄！

NECINA Annual Conference 

Co-host with HMS-CSSA 

Paul English

Founder/Co-Founder of Boston Venture Studio and Kayak

Paul is the founder of Boston Venture Studio. He has previously co-founded and successfully sold six startups-- Kayak, Lola, Moonbeam, GetHuman, Boston Light, and Intermute. He is also the founder of four impactful nonprofits, including Summits Educationin Haiti and Embrace Boston. Paul is the subject of Tracy Kidder’s book “ATruck Full of Money”. You can hear an interview with Paul on “How I Built This” with Guy Raz, and you can see his video from TEDxBoston in 2022. Paul received a BS and MS in computer science from the University of Massachusetts and was awarded an honorary doctorate in 2019. Paul was named Chief Technology Officer of the Year by the Mass Technology Leadership Council in 2009. In 2024, he was named in The Boston Globe's Tech Power Players 50.

Raju Kucherlapati Ph.D. , Paul C. Cabot Professor of Genetics and Professor of Medicine at Harvard Medical School,  the first Scientific Director of the Harvard Medical School-Partners HealthCare Center for Genetics and Genomics (HPCGG). 

Dr. Kucherlapaticontributed to gene targeting, homologous recombination, the Human GenomeProject, and the Cancer Genome Atlas Program. His lab conducted extensive colorectal cancer research and developed numerous genetically modified mouse models. He held leadership roles at NIH, NHGRI, and NCI, and served on editorial boards, including as editor-in-chief of Genomics. He is a fellow of AAAS, a member of the National Academy of Medicine, served on the Presidential Bioethics Commission, and advised CMS on lab test reimbursement.

Jeremy Jenkins, Head of Discovery Sciences, Novartis

Jeremy Jenkins joined Novartis as a postdoc in 2003, following a postdoc at Harvard Medical School and a PhD in Molecular Genetics from Ohio State University. He received the 2011 Corwin Hansch Award for contributions to the field of QSAR, and the 2017 Novartis Leading Scientist VIVA award for helping to develop the field of in silico chemical biology. His global research teams at Novartis focus on early drug discovery projects and enabling technologies for target ID and lead discovery.

Wei Ding, Professor of CS UMass Boston, IEEE Fellow, AAIA

Wei Ding earned her Ph.D. in Computer Science from the University of Houston in 2008. Wei Ding, a Professor of Computer Science at UMass Boston, is an IEEE Fellow and AAIA Fellow. She earned her Ph.D. from the University of Houston in 2008 and served as an NSF Program Director from 2019 to 2023. Her research focuses on data mining, machine learning, and AI, with applications in various sciences. She has over 140 research papers, a book, and three patents. Wei is an Associate Editor for several journals and has received numerous awards, including the NSF Director's Award in 2022 and the WISAY Distinguished Woman in Science Award in 2019

Jinjun Shi, Associate Professor, Harvard Medical School

Dr. Jinjun Shi is an Associate Professor at Harvard Medical School. His lab focuses on nanomedicine, drug delivery, biomaterials, RNA therapy, and immunotherapy. His immunonanotherapy technology led to clinical trials by Selecta Biosciences. His current research includes RNAi and mRNA delivery, immunonanotherapeutics, and stimuli-responsive biomaterials. He has authored over 95 papers and holds over 65 patents. His work has been cited over 22,000 times. He is a Fellow of the AIMBE and a Clarivate Highly Cited Researcher

Juan Pablo, Director of Github Copilot, Microsoft

Juan Pablo is a key figure at Microsoft, leading the development of Microsoft Copilot. With a strong background in AI and software engineering, he enhances Microsoft 365 applications by integrating AI-driven productivity tools. His work focuses on creating intuitive solutions that streamline workflows and drive digital transformation.

Hann Yew, Partner, McKinsey Co

Hann Yew has been a partner at McKinsey for 9 years and has an MBA from Harvard Business School. She focuses on accelerating access to life science innovations, counseling biopharmaceutical companies, hospitals, digital health startups, and VC/PE investors globally. Hann advises on leveraging digital and analytics in R&D, including clinical trials and AI/ML in drug discovery. She has led digital health business builds, developed health IT strategic roadmaps, and conducted VC/PE market scans on health tech topics.

Zhiyong Xie, Vice President, Xellar Biosystem

Dr. Zhiyong Xie is the vice president of Xellar Biosystem, leading the AI and data science platform for disease and treatment understanding using organ-on-chips technology. He previously worked at Pfizer for 19 years, focusing on study design, data analysis, and AI in preclinical studies, clinical trials, and drug safety research. Dr. Xie holds a Ph.D. in computer science from Arizona State University and a master's from Peking University. He completed post-doc training at the University of Pennsylvania.

Shirley Liu, CEO, GV20 Therapeutics

Dr. Shirley Liu is the co-founder and CEO of GV20 Therapeutics, a biopharmaceutical company focused on oncology. She earned her PhD in Biomedical Informatics from Stanford and was a Professor at Dana-Farber Cancer Institute and Harvard. Dr. Liu has published over 270 papers, holds an H-index of 120, and is a fellow of ISCB and AIMBE. She has received numerous awards, including the ISCB Innovator Award and the Benjamin Franklin Award.

Louise Liu, Co-Founder & CTO, Hill Research

Dr. Ruihua Liu, a serial entrepreneur in data science, is the Chief Data Officer at Hill Research. She earned her PhD from the Chinese Academy of Sciences and founded CB Payments (CBP) in 2018. At Yale University, she completed a postdoctoral fellowship in machine learning and biostatistics. Her pioneering work in fraud detection models led CBP to partner with the Bank of China's US branch in 2020, and she was named one of Forbes China's "Top 60 Outstanding Chinese Elites in North America" in 2021.